COMMUNIQUÉS West-GlobeNewswire

HNL Lab Medicine Expands Access to Diagnostic Testing with New Wilkes-Barre Patient Service Center
17/03/2026
WILKES-BARRE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine will expand its service footprint in Northeastern Pennsylvania with the opening of a new Patient Service Center (PSC) inside The Wright Center for [...]
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
17/03/2026
Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro [...]
Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19
17/03/2026
GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive [...]
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
17/03/2026
Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of [...]
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
17/03/2026
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene [...]
Former Peloton and Equinox Design Leader Cecilia Farooqi Joins Noom as Head of Product Design
17/03/2026
Industry veteran with 20 years of design experience in health, fitness and more further strengthens Noom’s product leadership and expertise PRINCETON, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Noom, the leading behavior [...]
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
17/03/2026
Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. ( [...]
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
17/03/2026
Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
17/03/2026
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson’s model of [...]
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
17/03/2026
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: [...]
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
17/03/2026
- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children - TransCon hGH showed a safety and tolerability profile comparable to [...]
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
17/03/2026
PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented [...]
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
17/03/2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1. [...]
CoRegen, Inc. Publishes Promising New Data Highlighting SRC-3 Engineered Regulatory T Cells as New Immunotherapy Platform
17/03/2026
Peer-reviewed study demonstrates tumor-eradicating activity and durable anti-tumor immunity in multiple preclinical solid tumor models Findings support the potential of SRC-3 gene disrupted regulatory T cells to expand [...]
PatchMD Named the World’s #1 Vitamin Patch Brand in 2026 — And It’s Not Even Close
17/03/2026
Independent research confirms PatchMD holds 18% global market share in a booming $800M+ category projected to hit $1.78 billion by 2032. LAS VEGAS, NV, March 17, 2026 (GLOBE NEWSWIRE) -- The vitamin patch industry just [...]
Organoid COMMONS Announces Formation of Governing Board, Appointment of Alliance Director, and Announces Open Call for New COMMONS Members
17/03/2026
SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- The Organoid COMMONS (Consortium for Organoid Manufacturing, Measurement, Optimization, and Network for Standards) is pleased to announce formal establishment of its first [...]
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
17/03/2026
Institutional Financing Interest Emerges for Receivables-Backed Financing Following Extensive Diligence UNIONDALE, NY, March 17, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a [...]
Sofwave Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Achieves Full-Year Profitability
17/03/2026
Record quarterly revenue in fourth quarter of $28.9M, +58% year-over-year growth; IFRS gross margin of 75.6% Fourth quarter pulse recurring revenue of $13.2M, +83% year-over-year growth Full fiscal year 2025 revenue of [...]
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
17/03/2026
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 [...]

Pages